Fulcrum Therapeutics, Inc. announced that on January 15, 2021, Owen Wallace, Chief Scientific Officer of the Company, notified the Company of his intent to resign to pursue a new career opportunity. Dr. Wallace is expected to continue in his current role until February 5, 2021. Following his resignation, Dr. Wallace will join the Company's Scientific Advisory Board. The Company expects Christopher Moxham to serve as Chief Scientific Officer following the effective date of Dr. Wallace's resignation. Dr. Moxham currently serves as the Company's Senior Vice President of Discovery.